背景:肺癌是阿尔及利亚男性中最常见的癌症,也是癌症相关死亡的主要原因。对阿尔及利亚肺癌的特征知之甚少。本研究旨在探讨阿尔及利亚非小细胞肺癌(NSCLC)患者的临床病理特征及预后。
方法:这项回顾性研究是在本巴迪斯大学康斯坦丁大学医院(2015-2023)进行的269例经病理证实的NSCLC病例。其中,95例患者纳入生存分析。根据患者的医疗记录调查临床病理和结果数据。
结果:这项研究显示男性占主导地位,性别比为5.7,平均年龄为61.8岁。组织学上,67.3%的病例患有腺癌(ADC)和22.7%的鳞状细胞癌(SCC)。ADC和SCC在女性(p=0.02)和男性(p=0.003)患者中更常见。分别。男性吸烟率估计为82.2%。超过28%的人是不吸烟者。其中50.7%是女性,并在较年轻的年龄(p=0.04)。我们的大多数患者(75.5%)在诊断时处于晚期。大约70%的患者接受化疗(CT)作为一线治疗,中位数诊断和治疗延迟4个月和1个月,分别。I-III和IV期的中位总生存期(mOS)估计为10.3和6.7个月,分别。其他对OS有负面影响的因素是年龄>65岁(p=0.01),以及IV期的症状(p=0.005)和合并症(p=0.004)的存在,在I-III期病例中,延迟治疗(p=0.03)和仅接受CT(p=0.03)。IV期中期无进展生存期(mPFS),III,和II患者分别为4.1、5.2和8.3个月,分别,并受到合并症的负面影响(第四阶段,p=0.03)并单独接受CT(II-III期,p=0.03)。
结论:在阿尔及利亚患者中,NSCLC出现在早期和晚期。ADC是最常见的组织学亚型,吸烟仍然是男性最重要的危险因素。此外,影响生存的预后因素是分期,年龄,合并症,症状,和治疗。因此,烟草控制,早期检测计划,获得新疗法可能是降低NSCLC发病率和死亡率的最佳策略。
BACKGROUND: Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death in men in Algeria. Little is known about the characteristics of lung cancer in Algeria. This study aimed to determine the clinicopathological characteristics and prognosis of non-small cell lung cancer (NSCLC) patients in Algeria.
METHODS: This retrospective study was performed on 269 pathologically confirmed cases of NSCLC at the Benbadis University Hospital of Constantine (2015-2023). Of these, 95 patients were included in the survival analysis. The clinicopathological and outcome data were investigated based on the patients\' medical records.
RESULTS: This study showed male predominance with sex ratio of 5.7, with a mean age of 61.8 years. Histologically, 67.3% of cases had adenocarcinoma (ADC) and 22.7% squamous cell carcinoma (SCC). ADC and SCC occurred more frequently in female (p = 0.02) and male (p = 0.003) patients, respectively. Smoking was estimated at 82.2% in men. Over 28% were non-smokers, of which 50.7% were women, and presented at younger age (p = 0.04). Most of our patients (75.5%) have an advanced stage at diagnosis. Around 70% of patients underwent chemotherapy (CT) as first-line treatment, with medians diagnostic and treatment delays of 4 and 1 months, respectively. The median overall survival (mOS) was estimated at 10.3 and 6.7 months in I-III and IV stages, respectively. Other factors that negatively impact OS were age > 65 years (p = 0.01), and the presence of symptoms (p = 0.005) and comorbidity (p = 0.004) in stage IV, and delayed treatment (p = 0.03) and receiving CT alone (p = 0.03) in stages I-III cases. Medians progression free survival (mPFS) in stage IV, III, and II patients were 4.1, 5.2, and 8.3 months, respectively, and negatively affected by the comorbidity (stage IV, p = 0.03) and receiving CT alone (stages II-III, p = 0.03).
CONCLUSIONS: NSCLC presents at an early age and advanced stage in Algerian patients. ADC is the most frequent histological subtype and smoking remains the most important risk factor in men. Furthermore, the prognostic factors affecting survival are stage, age, comorbidity, symptoms, and treatment. Thus, tobacco control, early detection program, and access to novel therapies may be the best strategies to reduce NSCLC morbidity and mortality.